Jonathan D. Root
Jonathan D. Root's purchase track record
Jonathan D. Root has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/24/2025 | CARL | $7.00M | -10.0% | -8.3% | +8.6% |
| 11/15/2021 | SPRY | $18K | -51.2% | -65.1% | -14.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CARL CFO Appointment and FY2026 Revenue Guidance Confirmed. Carlsmed announced Richard Heppenstall as its new chief financial officer, succeeding Leo Greenstein. The company also reaffirmed its FY2026 sales guidance of $74 million to $78 million, matching analyst estimates. BTIG kept its price target at $23 following the announcements.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Aquestive news highlights biotech valuation dynamics. Recent market discussion focused on Aquestive Therapeutics and the pricing of anaphylaxis drug success. While this news does not directly involve ARS Pharmaceuticals, it reflects broader sector sentiment regarding biotech valuations. ARS Pharmaceuticals is currently trading with an RSI of 37.5, indicating mild oversold conditions relative to its recent range.
Transaction History
| OMDA | ▲ Buy | Grant | 694 | $0 | 10/5/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 820 | $0 | 7/5/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 10,882 | $0 | 6/16/2026 | View on chart |
| CARL | ▲ Buy | Grant | 13,698 | $0 | 6/3/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 882 | $0 | 4/5/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 915 | $0 | 1/5/2026 | View on chart |
| OMDA | ▼ Sell | Other | 167,748 | $0 | 12/2/2025 | View on chart |
| OMDA | ▼ Sell | Other | 4,571,769 | $0 | 12/2/2025 | View on chart |
| OMDA | ▼ Sell | Other | 146,257 | $0 | 12/2/2025 | View on chart |
| OMDA | ▲ Buy | Grant | 657 | $0 | 10/5/2025 | View on chart |
| CARL | ▼ Sell | Other | 149,655 | — | 7/24/2025 | View on chart |
| CARL | ▼ Sell | Other | 531,877 | — | 7/24/2025 | View on chart |
| CARL | ▼ Sell | Other | 825,135 | — | 7/24/2025 | View on chart |
| CARL | ▼ Sell | Other | 2,948,794 | — | 7/24/2025 | View on chart |
| CARL | ▼ Sell | Other | 41,876 | — | 7/24/2025 | View on chart |
| CARL | ▼ Sell | Other | 26,993 | — | 7/24/2025 | View on chart |
| CARL | ▼ Sell | Other | 1,117,743 | — | 7/24/2025 | View on chart |
| CARL | ▲ Buy | Open Market | 466,666 | $7.0M | 7/24/2025 | View on chart |
| CARL | ▲ Buy | Grant | 17,333 | $0 | 7/22/2025 | View on chart |
| OMDA | ▲ Buy | Grant | 237 | $0 | 7/5/2025 | View on chart |
| OMDA | ▼ Sell | Other | 145,223 | — | 6/9/2025 | View on chart |
| OMDA | ▼ Sell | Other | 4,539,436 | — | 6/9/2025 | View on chart |
| OMDA | ▲ Buy | Grant | 9,736 | $0 | 6/5/2025 | View on chart |
| EWTX | ▼ Sell | Other | 3,473,543 | — | 2/25/2022 | View on chart |
| SPRY | ▼ Sell | Other | 2,069,167 | — | 12/13/2021 | View on chart |
| SPRY | ▼ Sell | Other | 105,012 | — | 12/13/2021 | View on chart |
| SPRY | ▲ Buy | Open Market | 2,014 | $18K | 11/15/2021 | View on chart |
| SPRY | ▲ Buy | Open Market | 350 | $18K | 3/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Omada Health Sets Q3 2026 Earnings Call, Investors Question Valuation
Omada Health will report its third quarter 2026 results on November 5 and host a conference call. Recent commentary highlights the company’s growth but raises concerns about its competitive moat and long‑term price targets. Analysts note a high trailing P/E of 260.2 and a wide target range of $22.00 to $35.00. The upcoming call may clarify how the firm plans to address these valuation questions.
Omada Health Sets Q3 2026 Earnings Call, Investors Question Valuation. Omada Health will report its third quarter 2026 results on November 5 and host a conference call. Recent commentary highlights the company’s growth but raises concerns about its competitive moat and long‑term price targets. Analysts note a high trailing P/E of 260.2 and a wide target range of $22.00 to $35.00. The upcoming call may clarify how the firm plans to address these valuation questions.